Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AAF Altachem Pharma -- Ignore unavailable to you. Want to Upgrade?

To: ciderapple who wrote (14)	5/26/1999 10:40:00 AM
From: terry	Read Replies (1) \| Respond to of 42

Thanks Roger....Here it is just in case anyone else is listening. Don't really know what to think other than we're entering a massive population with a "first"!! Terry ALTACHEM PHARMA LTD. - ANNOUNCES COMPLETION OF FORMULATION FOR BUFFERED ASPIRIN PROJECT EDMONTON, ALBERTA-- Warren Jackson, President and Chief Executive Officer of Altachem Pharma Ltd. (AAF), is pleased to announce the completion of the formulation for the Buffered Aspirin project. This is the first of six joint-venture agreements in place with China. AAF has formulated a 50-mg Buffered Aspirin tablet by using the local Chinese components (China's Active and Non-active ingredients). The product meets both the USP (United States Pharmacoepia) and Chinese standards. A complete technical File along with 3 different production batches containing ten thousand Buffered Aspirin tablets have been transferred to China, where our partners are currently performing the necessary pre-clinical (pharmacological and toxicological testings) and clinical studies for a successful registration of the Product with the Ministry of Public Health (MOPH). The manufacturing and distribution/marketing agreement is already in place with a Chinese pharmaceutical company, which has been in operation, manufacturing and distributing pharmaceutical tablets, creams, gels and injectables since 1957. AAF's royalties from gross sales are scheduled to start in the fourth quarter of 1999 and paid quarterly for seven years. Aspirin or Acetyl salicylic acid (ASA) is being frequently prescribed either alone, or in combination with other agents, for long term use in the prevention of myocardial infarction disease. In order to avoid gastric intolerance associated with the chronic use of the product, a buffered formulation was developed. Up to now, only enteric - coated Aspirin tablets are available in China. The 50 mg Buffered Aspirin tablet, which meets the standard of the Ministry of Public Health will be the first introduced to the local Chinese market. For more information, please visit our WEB site altachempharma.com or contact Warren Jackson at (780) 448-1400 or e-mail warren@altachempharma.com. For more information visit our World Wide Web page at internetstockmarket.com